Cargando…
Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India
We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated wit...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796192/ https://www.ncbi.nlm.nih.gov/pubmed/36573628 http://dx.doi.org/10.3201/eid2901.220926 |
| _version_ | 1784860426878582784 |
|---|---|
| author | Muthu, Valliappan Agarwal, Ritesh Rudramurthy, Shivaprakash Mandya Thangaraju, Deepak Shevkani, Manoj Radhakishan Patel, Atul K. Shastri, Prakash Srinivas Tayade, Ashwini Bhandari, Sudhir Gella, Vishwanath Savio, Jayanthi Madan, Surabhi Hallur, Vinay Kumar Maturu, Venkata Nagarjuna Srinivasan, Arjun Sethuraman, Nandini Sibia, Raminder Pal Singh Pujari, Sanjay Mehta, Ravindra Singhal, Tanu Saxena, Puneet Gupta, Varsha Nagvekar, Vasant Prayag, Parikshit Patel, Dharmesh Xess, Immaculata Savaj, Pratik Panda, Naresh Rajagopal, Gayathri Devi Parwani, Riya Sandeep Patel, Kamlesh Deshmukh, Anuradha Vyas, Aruna Sistla, Srinivas Kishore Padaki, Priyadarshini A Ramar, Dharshni Sarkar, Saurav Rachagulla, Bharani Vallandaramam, Pattabhiraman Premachandran, Krishna Prabha Pawar, Sunil Gugale, Piyush Hosamani, Pradeep Dutt, Sunil Narayan Nair, Satish Kalpakkam, Hariprasad Badhwar, Sanjiv Kompella, Kiran Kumar Singla, Nidhi Navlakhe, Milind Prayag, Amrita Singh, Gagandeep Dhakecha, Poorvesh Chakrabarti, Arunaloke |
| author_facet | Muthu, Valliappan Agarwal, Ritesh Rudramurthy, Shivaprakash Mandya Thangaraju, Deepak Shevkani, Manoj Radhakishan Patel, Atul K. Shastri, Prakash Srinivas Tayade, Ashwini Bhandari, Sudhir Gella, Vishwanath Savio, Jayanthi Madan, Surabhi Hallur, Vinay Kumar Maturu, Venkata Nagarjuna Srinivasan, Arjun Sethuraman, Nandini Sibia, Raminder Pal Singh Pujari, Sanjay Mehta, Ravindra Singhal, Tanu Saxena, Puneet Gupta, Varsha Nagvekar, Vasant Prayag, Parikshit Patel, Dharmesh Xess, Immaculata Savaj, Pratik Panda, Naresh Rajagopal, Gayathri Devi Parwani, Riya Sandeep Patel, Kamlesh Deshmukh, Anuradha Vyas, Aruna Sistla, Srinivas Kishore Padaki, Priyadarshini A Ramar, Dharshni Sarkar, Saurav Rachagulla, Bharani Vallandaramam, Pattabhiraman Premachandran, Krishna Prabha Pawar, Sunil Gugale, Piyush Hosamani, Pradeep Dutt, Sunil Narayan Nair, Satish Kalpakkam, Hariprasad Badhwar, Sanjiv Kompella, Kiran Kumar Singla, Nidhi Navlakhe, Milind Prayag, Amrita Singh, Gagandeep Dhakecha, Poorvesh Chakrabarti, Arunaloke |
| author_sort | Muthu, Valliappan |
| collection | PubMed |
| description | We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM. |
| format | Online Article Text |
| id | pubmed-9796192 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97961922023-01-09 Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India Muthu, Valliappan Agarwal, Ritesh Rudramurthy, Shivaprakash Mandya Thangaraju, Deepak Shevkani, Manoj Radhakishan Patel, Atul K. Shastri, Prakash Srinivas Tayade, Ashwini Bhandari, Sudhir Gella, Vishwanath Savio, Jayanthi Madan, Surabhi Hallur, Vinay Kumar Maturu, Venkata Nagarjuna Srinivasan, Arjun Sethuraman, Nandini Sibia, Raminder Pal Singh Pujari, Sanjay Mehta, Ravindra Singhal, Tanu Saxena, Puneet Gupta, Varsha Nagvekar, Vasant Prayag, Parikshit Patel, Dharmesh Xess, Immaculata Savaj, Pratik Panda, Naresh Rajagopal, Gayathri Devi Parwani, Riya Sandeep Patel, Kamlesh Deshmukh, Anuradha Vyas, Aruna Sistla, Srinivas Kishore Padaki, Priyadarshini A Ramar, Dharshni Sarkar, Saurav Rachagulla, Bharani Vallandaramam, Pattabhiraman Premachandran, Krishna Prabha Pawar, Sunil Gugale, Piyush Hosamani, Pradeep Dutt, Sunil Narayan Nair, Satish Kalpakkam, Hariprasad Badhwar, Sanjiv Kompella, Kiran Kumar Singla, Nidhi Navlakhe, Milind Prayag, Amrita Singh, Gagandeep Dhakecha, Poorvesh Chakrabarti, Arunaloke Emerg Infect Dis Synopsis We performed a case–control study across 25 hospitals in India for the period of January–June 2021 to evaluate the reasons for an COVID-19–associated mucormycosis (CAM) outbreak. We investigated whether COVID-19 treatment practices (glucocorticoids, zinc, tocilizumab, and others) were associated with CAM. We included 1,733 cases of CAM and 3,911 age-matched COVID-19 controls. We found cumulative glucocorticoid dose (odds ratio [OR] 1.006, 95% CI 1.004–1.007) and zinc supplementation (OR 2.76, 95% CI 2.24–3.40), along with elevated C-reactive protein (OR 1.004, 95% CI 1.002–1.006), host factors (renal transplantation [OR 7.58, 95% CI 3.31–17.40], diabetes mellitus [OR 6.72, 95% CI 5.45–8.28], diabetic ketoacidosis during COVID-19 [OR 4.41, 95% CI 2.03–9.60]), and rural residence (OR 2.88, 95% CI 2.12–3.79), significantly associated with CAM. Mortality rate at 12 weeks was 32.2% (473/1,471). We emphasize the judicious use of COVID-19 therapies and optimal glycemic control to prevent CAM. Centers for Disease Control and Prevention 2023-01 /pmc/articles/PMC9796192/ /pubmed/36573628 http://dx.doi.org/10.3201/eid2901.220926 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
| spellingShingle | Synopsis Muthu, Valliappan Agarwal, Ritesh Rudramurthy, Shivaprakash Mandya Thangaraju, Deepak Shevkani, Manoj Radhakishan Patel, Atul K. Shastri, Prakash Srinivas Tayade, Ashwini Bhandari, Sudhir Gella, Vishwanath Savio, Jayanthi Madan, Surabhi Hallur, Vinay Kumar Maturu, Venkata Nagarjuna Srinivasan, Arjun Sethuraman, Nandini Sibia, Raminder Pal Singh Pujari, Sanjay Mehta, Ravindra Singhal, Tanu Saxena, Puneet Gupta, Varsha Nagvekar, Vasant Prayag, Parikshit Patel, Dharmesh Xess, Immaculata Savaj, Pratik Panda, Naresh Rajagopal, Gayathri Devi Parwani, Riya Sandeep Patel, Kamlesh Deshmukh, Anuradha Vyas, Aruna Sistla, Srinivas Kishore Padaki, Priyadarshini A Ramar, Dharshni Sarkar, Saurav Rachagulla, Bharani Vallandaramam, Pattabhiraman Premachandran, Krishna Prabha Pawar, Sunil Gugale, Piyush Hosamani, Pradeep Dutt, Sunil Narayan Nair, Satish Kalpakkam, Hariprasad Badhwar, Sanjiv Kompella, Kiran Kumar Singla, Nidhi Navlakhe, Milind Prayag, Amrita Singh, Gagandeep Dhakecha, Poorvesh Chakrabarti, Arunaloke Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title | Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title_full | Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title_fullStr | Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title_full_unstemmed | Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title_short | Multicenter Case–Control Study of COVID-19–Associated Mucormycosis Outbreak, India |
| title_sort | multicenter case–control study of covid-19–associated mucormycosis outbreak, india |
| topic | Synopsis |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796192/ https://www.ncbi.nlm.nih.gov/pubmed/36573628 http://dx.doi.org/10.3201/eid2901.220926 |
| work_keys_str_mv | AT muthuvalliappan multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT agarwalritesh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT rudramurthyshivaprakashmandya multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT thangarajudeepak multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT shevkanimanojradhakishan multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT patelatulk multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT shastriprakashsrinivas multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT tayadeashwini multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT bhandarisudhir multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT gellavishwanath multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT saviojayanthi multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT madansurabhi multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT hallurvinaykumar multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT maturuvenkatanagarjuna multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT srinivasanarjun multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT sethuramannandini multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT sibiaraminderpalsingh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT pujarisanjay multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT mehtaravindra multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT singhaltanu multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT saxenapuneet multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT guptavarsha multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT nagvekarvasant multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT prayagparikshit multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT pateldharmesh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT xessimmaculata multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT savajpratik multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT pandanaresh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT rajagopalgayathridevi multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT parwaniriyasandeep multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT patelkamlesh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT deshmukhanuradha multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT vyasaruna multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT sistlasrinivaskishore multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT padakipriyadarshinia multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT ramardharshni multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT sarkarsaurav multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT rachagullabharani multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT vallandaramampattabhiraman multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT premachandrankrishnaprabha multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT pawarsunil multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT gugalepiyush multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT hosamanipradeep multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT duttsunilnarayan multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT nairsatish multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT kalpakkamhariprasad multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT badhwarsanjiv multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT kompellakirankumar multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT singlanidhi multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT navlakhemilind multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT prayagamrita multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT singhgagandeep multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT dhakechapoorvesh multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia AT chakrabartiarunaloke multicentercasecontrolstudyofcovid19associatedmucormycosisoutbreakindia |